2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

101. Red Cells and Erythropoiesis, Excluding Iron: Poster I

Program: Poster Abstract Session
Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Molecular Testing, Omics Technologies, Cell Expansion, Treatment Considerations, Combination Therapy, Drug Development, Supportive Care, Therapy Sequence, Biological Therapies, Antibody Therapy, Immunotherapy, Adverse Events, Artificial Intelligence (AI), Machine Learning, Biological Processes, Pathogenesis, Genomics, Hematopoiesis, Immune Mechanism, Metabolism, Molecular Biology, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Diseases, Bleeding and Clotting, Thromboembolism, Thrombotic Disorders, Bone Marrow Failure Syndromes, Genetic Disorders, Hemoglobinopathies, Thalassemia, Immunology, Autoimmune Hemolytic Anemia, Infectious Diseases, Myeloid Malignancies, Metabolic Disorders, Research, Fundamental Science, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Real-World Evidence, Registries, Study Population, Human, Adult, Pediatric, Young Adult
PAPER

1108 Comprehensive molecular analysis of non-polycythemia vera erythrocytosis: Genetic and clinical findings from a single-center cohort

Francesco Ramundo, MD, Tanja Malara2, Silvia Betti3, Monica Rossi4, Gessica Minnella5, Giuseppe Leone, MD6, Valerio De Stefano7, Elena Rossi, MD, PhD8, Patrizia Chiusolo, MD9
1 Section of Hematology, Department of Radiological and Hematological Sciences, Catholic University, Fondazione Policlinico Gemelli IRCCS, Rome, Italy
2 Section of Hematology, Department of Radiological and Hematological Sciences, Catholic University, Fondazione Policlinico Gemelli IRCCS, Rome, Italy
3 Section of Hematology, Department of Radiological and Hematological Sciences, Catholic University, Fondazione Policlinico Gemelli IRCCS, Rome, Italy
4 Section of Hematology, Department of Radiological and Hematological Sciences, Catholic University, Fondazione Policlinico Gemelli IRCCS, Rome, Italy
5 Section of Hematology, Department of Radiological and Hematological Sciences, Catholic University, Fondazione Policlinico Gemelli IRCCS, Rome, Italy
6 Section of Hematology, Department of Radiological and Hematological Sciences, Catholic University, Fondazione Policlinico Gemelli IRCCS, Rome, Italy
7 Section of Hematology, Department of Radiological and Hematological Sciences, Catholic University, Fondazione Policlinico Gemelli IRCCS, Rome, Italy
8 Section of Hematology, Department of Radiological and Hematological Sciences, Catholic University, Fondazione Policlinico Gemelli IRCCS, Rome, Italy
9 Section of Hematology, Department of Radiological and Hematological Sciences, Catholic University, Fondazione Policlinico Gemelli IRCCS, Rome, Italy
Background: Non-Polycythemia Vera (non-PV) erythrocytosis is a heterogeneous disorder, and the molecular basis remains unknown in many patients. Targeted next-generation sequencing (NGS) can enhance molecular characterization by detecting variants in genes related to oxygen sensing, erythropoietin (EPO) signaling, and erythropoiesis.

Methods:
We retrospectively evaluated all consecutive patients with erythrocytosis referred to our center from 2022 to 2025. Patients with a JAK2 V617F mutation and a variant allele frequency (VAF) greater than 2%, or a JAK2 exon 12 mutation were excluded. The remaining patients underwent  NGS using a custom gene panel that included EGLN1, EGLN2, VHL, ACO1, EPAS1, BPGM, EPOR, HIF1A, HBA1, HBA2, JAK2, MPL, NOTCH1, NOTCH2, NOTCH3, SH2B3, and THPO.

Results:
The cohort comprised 186 patients (156 males, 30 females). The median age was 56 years for males (range, 15–87) and 57 years for females (range, 35–83). Median hemoglobin (HB) and hematocrit (HCT) in males were 18.0 g/dL (range, 15.5–21.4) and 53.0% (range, 46.4–64.3), respectively. In females, median HB and HCT were 16.0 g/dL (range, 15.1–21.1) and 50.0% (range, 47.0–67.9), respectively. Serum erythropoietin (EPO) levels were available for 176 patients (94.6%), with a median of 10.6 mU/mL (range, 1.2–51; reference range, 4–19.5 mU/mL). Low-level JAK2 V617F variants were identified in 11 patients (5.9%), with a median VAF of 0.08% (range, 0.06–0.34%).
Potential secondary contributors included active smoking in 53 patients (28.5%), pulmonary disorders in 82 (44.1%), and SGLT2 inhibitor use in 16 (8.6%). Anabolic testosterone and cocaine use were reported in 2 (1.1%) and 1 patient (0.5%), respectively. Six patients (3.2%) had a history of kidney transplantation. EPO-secreting uterine myoma and hereditary hemochromatosis were each identified in one patient (0.5%). Cardiovascular risk factors were present in 79 patients (42.5%). Thrombotic events occurred in 35 patients (18.8%), with 15 arterial and 22 venous events. Therapeutic phlebotomy was performed in 47 patients (25.3%).
NGS identified germline variants in 56 patients (30.1%), categorized into hypoxia/oxygen-sensing-related genes (n=34), myeloid-associated genes (n=14), and hematopoietic signaling and iron homeostasis genes (n=12). The hypoxia/oxygen-sensing group included variants in NOTCH3 (n=9), EGLN1 (n=6), EGLN2 (n=4), EPAS1 (n=4), NOTCH1 (n=4), HIF1A (n=3), VHL (n=2), and NOTCH2 (n=2). The myeloid-associated group comprised SH2B3 (n=8), other JAK2 variants (n=4), and MPL (n=2). The hematopoietic signaling and iron homeostasis group included ACO1 (n=10), EPOR (n=1), and THPO (n=1). Multiple molecular alterations were found in 4 patients (2.1%), all involving NOTCH3, with two cases also carrying ACO1 variants, one with an additional JAK2 exon 25 variant, and one with a THPO variant. Variants were classified as pathogenic in 3 cases (5%), likely pathogenic in 15 (25%), and of uncertain significance in the remainder. No significant differences in HB, HCT, or serum EPO levels were observed among the three molecular categories (Kruskal–Wallis test, p>0.05). A positive family history of erythrocytosis was reported in 11 patients (5.9%). Molecular alterations were identified in 7 of these 11 patients (63.6%), compared with 49 of 175 patients (28%) without a family history (OR 4.5; 95%CI 1.26-16.1, p=0.02). Germline variants were detected in 13 of 35 patients (37.1%) with a history of thrombosis, compared with 43 of 151 patients (28.5%) without thrombotic events (OR 1.48; 95%CI 0.69-3.21, p=0.33). Arterial thrombosis occurred in 9 mutated and 6 unmutated patients (OR 3.79, 95%CI 1.28-11.23, p=0.02), while venous thrombosis occurred in 4 mutated and 16 unmutated patients (OR 0.54, 95%CI 0.17-1.72, p=0.3).

Conclusions:
In this large cohort of patients with non-PV erythrocytosis, targeted NGS identified molecular alterations in about one-third of cases, confirming the genetic heterogeneity of this disorder across multiple biological pathways. Molecular alterations were more common among patients with familial erythrocytosis and were significantly associated with arterial thrombosis. These findings underscore the value of molecular profiling for the biological characterization of non-PV erythrocytosis and may inform clinical management.
Patrizia Chiusolo, MD: Abbvie, Astellas and Otsuka - Honoraria